Middle East and Africa Generic Drugs Market Report and Forecast 2025-2034
Description
The Middle East and Africa generic drugs market was valued at USD 33.00 Billion in 2024, driven by increasing healthcare needs and strategic partnerships in the region. The market is expected to grow at a CAGR of 7.42% during the forecast period of 2025-2034, with the values likely to rise from USD 67.51 Billion by 2034.
Middle East and Africa Generic Drugs Market Analysis
A generic drug contains the same active ingredients and offers similar clinical benefits as a brand-name medicine. They are generally marketed at lower prices (an estimated 80 to 85% less ) and thus serve as a cost-effective alternative to patent-protected medications. Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, such as generic drugs . Further, the rising investment in healthcare infrastructure, such as hospitals and clinics, especially in under-developed areas, is expected to fuel the Middle East and Africa Generic Drugs market in the coming years.
The rising healthcare needs in the Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth, are significantly contributing to the expansion of the global generic drugs market . The International Diabetes Federation states that diabetes prevalence in the region is projected to reach 136 million cases by 2045. Additionally, obesity is a severe problem in the Middle East and Africa, comprising 18 of the top 50 countries with high obesity rates globally. With the growing prevalence of chronic conditions (needing long-term medications), the Middle East and Africa Generic Drugs market demand is expected to witness a surge in the forecast period.
One of the major market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023 , Cipla Limited, an Indian multinational pharmaceutical company signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African-based pharmaceutical company specializing in over the counter (OTC) and generic medicines, at a deal worth USD 48.6 million . The acquisition was intended to enter the South African market and strengthen its OTC drug offerings. Such collaborations also allow the regional players to utilize advanced technology and expertise, which helps them to improve the manufacturing efficiency and quality of generic drugs. Thus, the increasing merger and acquisition activities are anticipated to boost the market share.
Middle East and Africa Generic Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Area
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Middle East and Africa Generic Drugs Market Analysis
A generic drug contains the same active ingredients and offers similar clinical benefits as a brand-name medicine. They are generally marketed at lower prices (an estimated 80 to 85% less ) and thus serve as a cost-effective alternative to patent-protected medications. Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, such as generic drugs . Further, the rising investment in healthcare infrastructure, such as hospitals and clinics, especially in under-developed areas, is expected to fuel the Middle East and Africa Generic Drugs market in the coming years.
The rising healthcare needs in the Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth, are significantly contributing to the expansion of the global generic drugs market . The International Diabetes Federation states that diabetes prevalence in the region is projected to reach 136 million cases by 2045. Additionally, obesity is a severe problem in the Middle East and Africa, comprising 18 of the top 50 countries with high obesity rates globally. With the growing prevalence of chronic conditions (needing long-term medications), the Middle East and Africa Generic Drugs market demand is expected to witness a surge in the forecast period.
One of the major market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023 , Cipla Limited, an Indian multinational pharmaceutical company signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African-based pharmaceutical company specializing in over the counter (OTC) and generic medicines, at a deal worth USD 48.6 million . The acquisition was intended to enter the South African market and strengthen its OTC drug offerings. Such collaborations also allow the regional players to utilize advanced technology and expertise, which helps them to improve the manufacturing efficiency and quality of generic drugs. Thus, the increasing merger and acquisition activities are anticipated to boost the market share.
Middle East and Africa Generic Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Area
- Cardiovascular
- Dermatology
- Respiratory
- Oncology
- Rheumatology
- Others
- Oral
- Injectables
- Dermal/Topical
- Inhalers
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- UAE
- Saudi Arabia
- Egypt
- Others
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd
- Viatris Inc.
- AstraZeneca
- Baxter
- GSK plc
- Bausch + Lomb
- Novartis AG
- Sanofi
- Pfizer Inc.
- Fresenius SE & Co. KGaA
- Hikma Pharmaceuticals PLC
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Generic Drugs Market Overview
- 3.1 Middle East and Africa Generic Drugs Market Historical Value (2018-2024)
- 3.2 Middle East and Africa Generic Drugs Market Forecast Value (2025-2034)
- 4 Middle East and Africa Generic Drugs Market Landscape*
- 4.1 Middle East and Africa Generic Drugs: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Middle East and Africa Generic Drugs: Product Landscape
- 4.2.1 Analysis by Therapy Area
- 4.2.2 Analysis by Route of Administration
- 4.2.3 Analysis by Distribution Channels
- 5 Middle East and Africa Generic Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Middle East and Africa Generic Drugs Market Segmentation (218-2034)
- 6.1 Middle East and Africa Generic Drugs Market (2018-2034) by Therapy Area
- 6.1.1 Market Overview
- 6.1.2 Cardiovascular
- 6.1.3 Dermatology
- 6.1.4 Respiratory
- 6.1.5 Oncology
- 6.1.6 Rheumatology
- 6.1.7 Others
- 6.2 Middle East and Africa Generic Drugs Market (2018-2034) by Route of Administration
- 6.2.1 Market Overview
- 6.2.2 Oral
- 6.2.3 Injectables
- 6.2.4 Dermal/Topical
- 6.2.5 Inhalers
- 6.2.6 Others
- 6.3 Middle East and Africa Generic Drugs Market (2018-2034) by Distribution Channels
- 6.3.1 Market Overview
- 6.3.2 Hospital Pharmacy
- 6.3.3 Retail Pharmacy
- 6.3.4 Online Pharmacy
- 6.3.5 Others
- 6.4 Middle East and Africa Generic Drugs Market (2018-2034) by Country
- 6.4.1 Market Overview
- 6.4.2 UAE
- 6.4.3 Saudi Arabia
- 6.4.4 Egypt
- 6.4.5 Others
- 7 UAE Generic Drugs Market Segmentation (218-2034)
- 7.1 UAE Generic Drugs Market (2018-2034) by Therapy Area
- 7.1.1 Market Overview
- 7.1.2 Cardiovascular
- 7.1.3 Dermatology
- 7.1.4 Respiratory
- 7.1.5 Oncology
- 7.1.6 Rheumatology
- 7.1.7 Others
- 7.2 UAE Generic Drugs Market (2018-2034) by Route of Administration
- 7.2.1 Market Overview
- 7.2.2 Oral
- 7.2.3 Injectables
- 7.2.4 Dermal/Topical
- 7.2.5 Inhalers
- 7.2.6 Others
- 8 Saudi Arabia Generic Drugs Market Segmentation (218-2034)
- 8.1 Saudi Arabia Generic Drugs Market (2018-2034) by Therapy Area
- 8.1.1 Market Overview
- 8.1.2 Cardiovascular
- 8.1.3 Dermatology
- 8.1.4 Respiratory
- 8.1.5 Oncology
- 8.1.6 Rheumatology
- 8.1.7 Others
- 8.2 Saudi Arabia Generic Drugs Market (2018-2034) by Route of Administration
- 8.2.1 Market Overview
- 8.2.2 Oral
- 8.2.3 Injectables
- 8.2.4 Dermal/Topical
- 8.2.5 Inhalers
- 8.2.6 Others
- 9 Egypt Generic Drugs Market Segmentation (218-2034)
- 9.1 Egypt Generic Drugs Market (2018-2034) by Therapy Area
- 9.1.1 Market Overview
- 9.1.2 Cardiovascular
- 9.1.3 Dermatology
- 9.1.4 Respiratory
- 9.1.5 Oncology
- 9.1.6 Rheumatology
- 9.1.7 Others
- 9.2 Egypt Generic Drugs Market (2018-2034) by Route of Administration
- 9.2.1 Market Overview
- 9.2.2 Oral
- 9.2.3 Injectables
- 9.2.4 Dermal/Topical
- 9.2.5 Inhalers
- 9.2.6 Others
- 10 Regulatory Framework
- 10.1 Regulatory Overview
- 10.1.1 MOHAP UAE
- 10.1.2 SFDA Saudi Arabia
- 11 Patent Analysis
- 11.1 Analysis by Type of Patent
- 11.2 Analysis by Publication year
- 11.3 Analysis by Issuing Authority
- 11.4 Analysis by Patent Age
- 11.5 Analysis by CPC Analysis
- 11.6 Analysis by Patent Valuation
- 11.7 Analysis by Key Players
- 12 Grants Analysis
- 12.1 Analysis by Year
- 12.2 Analysis by Amount Awarded
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Grant Housing Material
- 12.5 Analysis by Funding Institute
- 12.6 Analysis by Departments
- 12.7 Analysis by Recipient Organization
- 13 Funding and Investment Analysis
- 13.1 Analysis by Funding Instances
- 13.2 Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1 Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4 Analysis by Geography
- 15 Supplier Landscape
- 15.1 Market Share by Top 5 Companies
- 15.2 Teva Pharmaceutical Industries Ltd
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Viatris Inc.
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 AstraZeneca
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Baxter
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 GSK plc
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Bausch + Lomb
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Novartis AG
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 Sanofi
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Pfizer Inc.
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 15.11 Fresenius SE & Co. KGaA
- 15.11.1 Financial Analysis
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisitions
- 15.11.5 Certifications
- 15.12 Hikma Pharmaceuticals PLC
- 15.12.1 Financial Analysis
- 15.12.2 Product Portfolio
- 15.12.3 Demographic Reach and Achievements
- 15.12.4 Mergers and Acquisitions
- 15.12.5 Certifications
- 16 Middle East and Africa Generic Drugs Market – Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
